(4-chloro-5-trifluoromethyl-pyrimidin-2-yl)-(4-methylbenzyl)-amine | 847863-14-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-chloro-5-trifluoromethyl-pyrimidin-2-yl)-(4-methylbenzyl)-amine
• 英文别名: 4-chloro-N-[(4-methylphenyl)methyl]-5-(trifluoromethyl)pyrimidin-2-amine
• CAS: 847863-14-3
• 化学式: C₁₃H₁₁ClF₃N₃
• 分子量: 301.699
• InChiKey: RXLUXCFXLDCISZ-UHFFFAOYSA-N

物化性质

• 沸点：
  416.1±55.0 °C(Predicted)
• 密度：
  1.385±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,4-二氯-5-三氟甲基嘧啶 、 4-甲基苄胺 在 zinc(II) chloride 、 三乙胺 作用下， 以 乙醚 、 1,2-二氯乙烷 、 叔丁醇 为溶剂， 生成 (4-chloro-5-trifluoromethyl-pyrimidin-2-yl)-(4-methylbenzyl)-amine 、
  参考文献：
  名称：

  Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids

  摘要：

  A variety of 2,4-diamino-pyrimidine systems can be prepared from the corresponding 2,4-dichloropyrimidine by sequential addition of two amines, the first adding selectively to the 4-position. In contrast it was found that 2,4-dichloro-5-trifluoromethyl-pyrimidine yields a 1:1 mixture of the two possible isomers. Lewis acids were employed to increase the ratio of isomers to >10:1 in favor of the 2-addition product. Optimization of the effect of Lewis acid additives on this and other dichloropyrimidine systems will be discussed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2013.06.025

文献信息

• [EN] SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES<br/>[FR] SYNTHÈSE SÉLECTIVE DE PYRIMIDINES SUBSTITUÉES EN CF3
  申请人：PFIZER PROD INC

  公开号：WO2005023780A1

  公开（公告）日：2005-03-17

  The present invention relates to a method of making a compound of the formula (I),wherein X1, X2 and R3-R4 are as defined herein. The method includes reacting a compound of the formula (II) with an amine of formula (III) (HNR3R4) in the presence of a Lewis Acid and a non-nucleophilic base. The 2,4-diamino pyrimidine moiety is a common component in a variety of biologically active drug-like molecules and pyrimidine derivatives have been found to be useful in the 10 treatment of abnormal cell growth, such as cancer, in mammals.

  本发明涉及一种制备公式（I）化合物的方法，其中X1、X2和R3-R4如本文所定义。该方法包括在路易斯酸和非亲核碱存在下，将公式（II）化合物与公式（III）胺（HNR3R4）反应。2,4-二氨基嘧啶基团是各种生物活性类药物分子中的常见组分，已发现嘧啶衍生物在哺乳动物的异常细胞生长治疗中很有用，例如癌症治疗。
• Selective synthesis of CF3-substituted pyrimidines
  申请人：Kath Charles John

  公开号：US20050101620A1

  公开（公告）日：2005-05-12

  The present invention relates to a method of making a compound of the formula wherein X 1 , X 2 and R 3 —R 4 are as defined herein. The method includes reacting a compound of the formula with an amine of formula 3 (HNR 3 R 4 ) in the presence of a Lewis Acid and a non-nucleophilic base. The 2,4-diamino pyrimidine moiety is a common component in a variety of biologically active drug-like molecules and pyrimidine derivatives have been found to be useful in the treatment of abnormal cell growth, such as cancer, in mammals.

  本发明涉及一种制备化合物的方法，该化合物的结构式为其中X1，X2和R3-R4如定义所示。该方法包括在路易斯酸和非亲核碱存在下，将式化合物与式3的胺反应。2,4-二氨基嘧啶基团是各种生物活性药物分子中的常见组成部分，已发现嘧啶衍生物在治疗哺乳动物异常细胞生长（如癌症）方面非常有用。
• SELECTIVE SYNTHESIS OF CF3-SUBSTITUTED PYRIMIDINES
  申请人：Pfizer Products Inc.

  公开号：EP1663991B1

  公开（公告）日：2007-01-10
• US7122670B2
  申请人：——

  公开号：US7122670B2

  公开（公告）日：2006-10-17
• Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids
  作者：Daniel T. Richter、John C. Kath、Michael J. Luzzio、Nandell Keene、Martin A. Berliner、Matthew D. Wessel

  DOI：10.1016/j.tetlet.2013.06.025

  日期：2013.8

  A variety of 2,4-diamino-pyrimidine systems can be prepared from the corresponding 2,4-dichloropyrimidine by sequential addition of two amines, the first adding selectively to the 4-position. In contrast it was found that 2,4-dichloro-5-trifluoromethyl-pyrimidine yields a 1:1 mixture of the two possible isomers. Lewis acids were employed to increase the ratio of isomers to >10:1 in favor of the 2-addition product. Optimization of the effect of Lewis acid additives on this and other dichloropyrimidine systems will be discussed. (C) 2013 Elsevier Ltd. All rights reserved.